| Identification | Back Directory | [Name]
3-(2-Cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide | [CAS]
850607-58-8 | [Synonyms]
GSK233705
GSK-233705
GSK 233705
GSK 233705B
DarotropiuM broMide
CWRNUVNMUYSOFQ-XITXYIRHSA-M
3-(2-Cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide | [Molecular Formula]
C24H29N2.Br | [MDL Number]
MFCD16660962 | [MOL File]
850607-58-8.mol | [Molecular Weight]
425.41 |
| Hazard Information | Back Directory | [Uses]
Darotropium bromide (GSK233705), a long-acting muscarinic antagonist and an inhaled anticholinergic, can be used for the research of chronic obstructive pulmonary disease (COPD)[1][2]. | [References]
[1] Jutta Beier, et al. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. Int J Chron Obstruct Pulmon Dis. 2012:7:153-64. DOI:10.2147/COPD.S26100
[2] Eric Bateman, et al. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. Clin Respir J. 2012 Oct;6(4):248-57. DOI:10.1111/j.1752-699X.2011.00278.x |
|
| Company Name: |
Carbosynth
|
| Tel: |
+86 512 6260 5585 |
| Website: |
www.carbosynth.com |
|